Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    17962618 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer
Conditions: Gastric Cancer;   Histone Deacetylase Inhibitor
Intervention: Drug: Vorinostat, capecitabine, and cisplatin

Indicates status has not been verified in more than two years